Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Inclusion Criteria: * Participant with T2DM on stable non-insulin antidiabetic therapy in addition to diet and exercise * Body mass index (BMI) ≥ 25 kg/m\^2 and ≤ 40 kg/m\^2 * HbA1c 7 - 11% * Ability and willingness to maintain a complete and accurate Subject Activity Log during the course of the trial * Female of child-bearing potential must have agreed to use effective methods of contraception * Ability to understand and willing to sign written informed consent Exclusion Criteria: * Type 1 Diabetes Mellitus (T1DM) * T2DM with history of or current insulin therapy. Prior use during pregnancy or gestational diabetes was acceptable. * History of ketoacidosis or ketosis-prone diabetes * Clinically significant complications of diabetes that in the judgment of the investigator would have made participant unsuitable to participate in this trial * History of a severe episode of hypoglycemia * Change in non-insulin antidiabetic therapy in addition to diet and exercise \< 2 months prior to screening * Any clinically significant cardiovascular event \< 2 months prior to screening * Clinically significant, inadequately controlled or unstable hypertension * Hospitalization \< 2 months prior to screening * Major surgery \< 3 months prior to screening * Weight loss medication (prescription or non-prescription) \< 2 months prior to screening